Nexstim Plc · OMXHEX:NXTMH
Nexstim — Nexstim Plc Corporate Presentation Webinar 15 May 2020
26 slides from Nexstim's conference presentation, May 15, 2020
Slide 1: Nexstim. Personalised depression treatment.
Nexstim. Personalised depression treatment. Mikko Karvinen| CEO | Nexstim Plc Nexstim Plc Corporate Presentation Webinar, 15 May 2020
Slide 2: Important Information
Important Information This document and the information contained herein are being presented by Nexstim Oyj other than the date of this presentation. Nothing contained herein is, or should be relied upon (“Nexstim” or the “Company”). In connection with any presentation or review of this document, as
Slide 3: We enable personalised and effective therapies and diagnostics
We enable personalised and effective therapies and diagnostics for challenging brain diseases and disorders
Slide 4: Nexstim – personalised transcranial magnetic stimulation (TMS)
Nexstim – personalised transcranial magnetic stimulation (TMS) Unique and Proprietary ▪ Commercial-stage med tech company with a unique, proprietary navigated neuro- Technology stimulation technology for diagnostic and therapeutic applications World Leading Centers Rely ▪ Diagnostic application well
Slide 5: Nexstim's TMS system differentiated by E-Field Navigation
Nexstim’s TMS system differentiated by E-Field Navigation Leading transcranial magnetic stimulation technology User Interface of Nexstim TMS system • Nexstim’s device facilitates highly accurate pre-surgical mapping • Unique e-field induced modelling • 3D MRI visualisation and stereotactic navigatio
Slide 6: Unique navigated TMS system for diagnostic and therapeutic applications
Unique navigated TMS system for diagnostic and therapeutic applications Use Application Europe US Commercial Status Diagnostic – Installed base of over Navigated Brain Pre-surgical mapping CE marked FDA approved 170 systems Stimulation (NBS) Multiple systems Therapeutic – Depression CE marked FDA ap
Slide 7: Nexstim SmartFocus TMS in diagnostics
Nexstim SmartFocus® TMS in diagnostics Proprietary technology enabling substantial increase in progression- free survival in brain cancer surgery, commercially validated
Slide 8: Nexstim's NBS is the only available pre-surgical mapping technology
Nexstim’s NBS is the only available pre-surgical mapping technology World-leading Centers Rely on Nexstim‘s Pre-surgical NBS Significantly Improves Clinical Outcomes Mapping Technology NBS Selected institutions out of the 170 ones currently NBS helps surgeons to prepare better and to be more aggress
Slide 9: Nexstim SmartFocus TMS in Therapy
Nexstim SmartFocus® TMS in Therapy Smart, focused and drug-free
Slide 10: Nexstim E-field navigation vs. line navigation
Nexstim E-field navigation vs. line navigation Line Nexstim navigated TMS coil TMS coil • Line navigation is inaccurate as it doesn’t E-field target E-field target Line navigation account for the distortion misses target caused by bone and brain matter • Nexstim’s E-field navigation accounts for tha
Slide 11: Nexstim SmartFocus TMS in Depression
Nexstim SmartFocus® TMS in Depression Entering a rapidly growing market with a differentiated product
Slide 12: TMS in Depression Treatment
TMS in Depression Treatment • In depression, activity of the left dorsolateral prefrontal cortex (DLPFC) is reduced* • Stimulation of the DLPFC with rTMS increases the activity of neurons in this region* • 2nd or 3rd line therapy for patients not responding to anti-depressants or psychotherapy • Alt
Slide 13: NBT for Depression
NBT® for Depression Nexstim depression business opportunity Market size estimate2 (patients) People affected by MDD globally 216m • Major depressive disorder affects 2-5% of the Patients not responding to medicines population in developed countries1 39m and seeking treatment • Existing psychotherapy
Slide 14: Existing reimbursement for depression treatment and private pay in the US
Existing reimbursement for depression treatment and private pay represent compelling opportunity in the US Economic Benefit to US TMS Centre or Psychiatric Clinic Commercialisation approach (Pay-per-use lease)1 • Most major commercial payers now reimburse TMS treatment for depression in the US and 1
Slide 15: Promising Clinical Outcomes - Patients Completing SmartFocus rTMS Treatment of MDD
Promising Clinical Outcomes - Patients Completing SmartFocus® rTMS Treatment of MDD • First 55 patients in Nexstim’s patient registry have completed SmartFocus® rTMS therapy for treatment of MDD at clinical sites in the US. • 40% of the patients completing the treatment achieved clinical remission a
Slide 16: Accelerated iTBS therapy published by the Stanford team
Accelerated iTBS therapy published* by the Stanford team is a perfect match for Nexstim’s accurate targeting • Accelerated iTBS combines patient-specific individualized targeting of rTMS (A), accelerated delivery of hourly sessions (B) and high pulse-dose [both per session (B) and overall (C)]. • A)
Slide 17: Commercialization and Go-To Market Approach – Europe & Asia
Nexstim Brain Therapy - Commercialization and Go- To Market Approach – Europe & Asia Actions on established markets • Strong distributor organization • Cross-selling NBS with NBT® • Five university hospitals in Finland using a Nexstim system for both depression and pain treatments • A growing patien
Slide 18: Nexstim SmartFocus TMS in Chronic Neuropathic Pain
Nexstim SmartFocus® TMS in Chronic Neuropathic Pain
Slide 19: NBT for Chronic Neuropathic Pain
NBT® for Chronic Neuropathic Pain Nexstim neuropathic pain business opportunity Market size of estimate2 People affected by chronic • There are about 10 million addressable neuropathic pain 285m neuropathic pain annually patients in the US and Europe1 Patients not responding to medicines and seeking
Slide 20: Nexstim Therapy Business Update Full Year 2019
Nexstim Therapy Business Update Full Year 2019 ▪ The company’s NBT® therapy system installed base grew to a total of 23 systems at end of year 2019 ▪ The US NBT® system installed base was a total of 10 systems and in Europe and rest of the world a total of 13 NBT® systems ▪ Therapy revenue grew by 1
Slide 21: Key Performance Indicators and Outlook for 2020
Key Performance Indicators and Outlook for 2020 EUR in thousands FY 2019 FY 2018 Net sales grew by 25%. Therapy business net sales grew 12 months 12 months strongly (131%) in 2019 amounting to EUR 1,522.9 thousand (2018: EUR 659.9 thousand) Net sales 3,348.1 2,672.1 The increase in personnel expense
Slide 22: Financial and Business Update
Financial and Business Update COVID-19 triggered cost saving measures will reach savings of approximately EUR 0.8 million 1 during Apr-Jun 2020. Development of the business environment will be closely monitored Decision pursuant to the authorisation granted by the AGM on 30 April 2020, to arrange a
Slide 23: Nexstim Rights Issue 2020
Nexstim Rights Issue 2020 All parties investing in Nexstim are advised to acquaint themselves with the Basic Details Document which is available at www.nexstim.com/investors/rights-issue- 2020 15 May 2020 Public Presentation Nexstim Plc 23
Slide 24: Thank you!
Thank you! It‘s time for possible questions now: Please use the Q&A Chat
Slide 25: The Board of Directors
Appendix The Board of Directors Name Education Relevant experience Nationality Currently Niemistö is a board member of four publicly listed companies in Finland. She is also an active investor Leena Niemistö, MD and a PhD from the University of in health-tech growth companies. Niemistö’s investment
Slide 26: Management team
Appendix Management team Name Current position (Nexstim Education Relevant experience Nationality since) Previously CFO at Nexstim since 2014. MSc in economics at Helsinki School of Held CFO and deputy CEO positions at Mikko Karvinen CEO Economics (2001), EMBA at Aalto University, two Nasdaq OMX lis
Nexstim — Nexstim Plc Corporate Presentation Webinar 15 May 2020 on 6ix